San Diego Life Science Sector Set to Outperform Other Asset Classes

The San Diego life science sector is set to outperform other assets classes during the downturn. According to a new report from JLL, venture capital spending will help to prop up the industry. In the first quarter, life science companies secured $5 billion in venture capital funding in the San Diego market, and $315 million in healthcare alone.

“Analysts see the COVID-19 pandemic continuing to fuel more growth and demand for Life Science research and development,” Grant Schoneman, managing director at JLL, tells GlobeSt.com. “The continued push for more testing to fight the coronavirus, coupled with the ongoing need to produce more effective technologies to treat cancer, diabetes, neurological and other diseases will continue to drive investment into the life sciences sector.”